Scarica l'app Stockscreener
18.89
1.23%
0.23
Dopo l'orario di chiusura:
18.89
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Precedente Chiudi:
$18.66
Aprire:
$18.3
Volume 24 ore:
3.00M
Relative Volume:
0.98
Capitalizzazione di mercato:
$4.14B
Reddito:
$10.68M
Utile/perdita netta:
$-272.71M
Rapporto P/E:
-12.07
EPS:
-1.565
Flusso di cassa netto:
$-213.38M
1 W Prestazione:
-0.63%
1M Prestazione:
-5.27%
6M Prestazione:
+76.71%
1 anno Prestazione:
+365.27%
Intervallo 1D:
$18.10
$19.11
Intervallo di 1 settimana:
$18.10
$19.28
Portata 52W:
$3.885
$21.27
Relay Therapeutics Inc Stock (RLAY) Company Profile
Nome
Relay Therapeutics Inc
Settore
Industria
Telefono
617-370-8837
Indirizzo
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
18.89 | 4.09B | 10.68M | -272.71M | -213.38M | -1.565 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-12-12 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-04-17 | Iniziato | Wells Fargo | Equal Weight |
| 2024-09-10 | Ripresa | Goldman | Buy |
| 2024-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-05-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-04-20 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-04-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | Iniziato | Raymond James | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-09-30 | Iniziato | Barclays | Equal Weight |
| 2022-09-02 | Iniziato | Stifel | Buy |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-02-01 | Iniziato | Berenberg | Buy |
| 2021-07-21 | Iniziato | BofA Securities | Buy |
| 2020-12-15 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-11-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-10 | Iniziato | Cowen | Outperform |
| 2020-08-10 | Iniziato | Goldman | Buy |
| 2020-08-10 | Iniziato | Guggenheim | Buy |
| 2020-08-10 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Relay Therapeutics CEO Sanjiv Patel sells 48,199 shares for $912,889.06 - Bitget
Relay Therapeutics (RLAY) Insider Sell: President, R&D Donald Be - GuruFocus
Relay Therapeutics R&D president sells $161,814 in stock By Investing.com - Investing.com South Africa
Relay Therapeutics R&D president sells $161,814 in stock - Investing.com
Relay Therapeutics (RLAY) R&D chief sells stock under 10b5-1 plan - Stock Titan
Relay Therapeutics (RLAY) CFO sells about $335K in stock under preset plan - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) CEO sells shares under preset trading plan - Stock Titan
Why Is RLAY Stock Rising Today? - Stocktwits
Relay Therapeutics at Wells Fargo conference: pipeline nears key tests By Investing.com - Investing.com Canada
RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits
Relay Therapeutics CFO Sells 17,717 Shares for $350,000 - finance.yahoo.com
Relay Therapeutics to Participate in Upcoming September Healthcare Conference Fireside Chats - Quiver Quantitative
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - GlobeNewswire
Relay Therapeutics (RLAY) Insider Peter Rahmer Sells 4,508 Shares - GuruFocus
Relay Therapeutics (RLAY) exec sells 4,508 shares under plan - Stock Titan
SoftBank Vision Fund Subsidiary Sells 6 Million Shares of Relay Therapeutics at $19.4 Each - Kalkine Media
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m By Investing.com - Investing.com Canada
Relay Therapeutics (NASDAQ: RLAY) 10% owner SoftBank sells 6M shares - Stock Titan
Relay Therapeutics director SVF Pauling (Cayman) sells $116.4m - Investing.com
Relay Therapeutics (NASDAQ: RLAY) officer eyes another stock sale after June trade - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) holder plans sale of up to 6M shares - Stock Titan
What is HC Wainwright's Estimate for RLAY FY2027 Earnings? - MarketBeat
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $29 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Relay Therapeutics price target to $29 By Investing.com - Investing.com Canada
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE - MarketBeat
Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified? - Yahoo Finance
Relay Therapeutics (RLAY) Stock May Be Fully Valued After A 7x Run - simplywall.st
Timothy G. Youngquist 2020 Irrevocable Trust Boosts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Handelsbanken Fonder AB Buys New Shares in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Insider Sold Shares Worth $979,886, According to a Recent SEC Filing - marketscreener.com
Relay Therapeutics (RLAY) CEO sells 48K shares in plan trade - Stock Titan
Relay Therapeutics (RLAY) CFO sells shares via preset trading plan - Stock Titan
Relay (RLAY) Earnings Metrics: EPS Does Not Reach the Reported Estimate in Latest Trading - Vinanet
Relay Therapeutics stock hits 52-week high at 20.83 USD By Investing.com - Investing.com Canada
Relay Therapeutics stock hits 52-week high at 20.83 USD - Investing.com
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - The Globe and Mail
Alphabet Inc. Makes New Investment in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Persistent Asset Partners Ltd Makes New $1.32 Million Investment in Relay Therapeutics, Inc. $RLAY - MarketBeat
Elmind Capital, LP's Relay Therapeutics Inc(RLAY) Holding History - GuruFocus
Relay Therapeutics (RLAY) Slips 0.35% as Shares Trade Near Midpoint of Key RangeValue Area Low - vinanet.vn
Relay Therapeutics (NASDAQ:RLAY) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
PERCEPTIVE ADVISORS LLC Expands Relay Therapeutics Inc (RLAY) St - GuruFocus
Relay Therapeutics (RLAY): Commodore Capital group discloses 12M-share, 5.5% position - Stock Titan
J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $31 - Moomoo
RLAY Maintained by JP Morgan -- Price Target Raised to $31.00 - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year - Barchart.com
Relay Therapeutics, Inc. $RLAY Shares Bought by California State Teachers Retirement System - MarketBeat
Relay Therapeutics Inc Azioni (RLAY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):